Trial
NCT05543252
An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
UCB Biopharma SRL
Collaborators
—
Condition
Parkinson's Disease
Intervention
Minzasolmin (UCB0599)
Why stopped
Based on available data, the decision was made to stop development of UCB0599/minzasolmin as treatment of Parkinson's Disease.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-02